Glioblastoma, the most common and most lethal adult brain malignancy, remains highly refractory to most treatment approaches.

A combination treatment for advanced liver cancer appears to do something remarkable inside the tumor itself: it helps build ...

Melanoma remains one of the most aggressive human cancers, arising from the pigment-producing melanocytes of the skin and, ...

After three patient deaths and the indefinite suspension of several clinical trials, questions exist about the potential future of CAR T-cell research for autoimmune diseases.

Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with ...

CAR-T therapy reprograms autologous T cells to recognize leukemia, is generally reserved for relapsed/refractory B-cell ALL, and can provide ongoing immune surveillance when cells persist. Post–CAR-T ...

AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Cystic adenocarcinoma (marked in red) of the pancreas (outlined in green). Contrast‑enhanced ...

Researchers at The University of Texas MD Anderson Cancer Center have traced how off-the-shelf chimeric antigen receptor (CAR ...

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, ...

The new trial (NCT07680673) will bring ENCRT-103-hPI, Encellin's immune-protected implant configuration, into the clinic. ENCRT-103-hPI builds on the successful completion of NCT06408311, Encellin's ...

Researchers at the Francis Crick Institute, King's College London and Complutense University of Madrid have shown that γδ T ...